Status:
COMPLETED
RW Effectiveness of Lurbinectedin in Extensive Stage SCLC
Lead Sponsor:
Intergroupe Francophone de Cancerologie Thoracique
Collaborating Sponsors:
Groupe Francais De Pneumo-Cancerologie
PharmaMar
Conditions:
Small-cell Lung Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
LURBICLIN cohort will describe the demographic and clinical characteristics of patients who received at least one dose of lurbinectedin as part of ATU program. LURBICLIN will evaluate effectiveness an...
Detailed Description
LURBICLIN cohort will describe the demographic and clinical characteristics of patients who received at least one dose of lurbinectedin as part of ATU program. LURBICLIN will evaluate overall survival...
Eligibility Criteria
Inclusion
- Patients with histologically or cytologically confirmed extensive stage Small Cell Lung Cancer
- Patients who were informed about the study and accepted for their data to be collected
- Patients who received at least one dose of treatment with lurbinectedin as part of the French Early Access Program (ATU program).
- Selection period spans from June 2020 until March 2021 for initiation of treatment with lurbinectedin.
Exclusion
- Patients enrolled in a clinical trial assessing treatment with lurbinectedin
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 15 2022
Estimated Enrollment :
312 Patients enrolled
Trial Details
Trial ID
NCT05285033
Start Date
April 1 2022
End Date
December 15 2022
Last Update
January 6 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Curie
Paris, France
2
Villefranche-Sur-Saône - CH
Villefranche-sur-Saône, France